CD274 and small cell lung carcinoma: In the KEYNOTE-028 Phase Ib study or pembrolizumab in patients with PD-L1positive solid tumors, only 42 of 147 SCLC patients (28.6%) were found to have tumoral PD-L1 expression as determined by immunohistochemistry.